Reuters logo
BRIEF-Aevi Genomic Medicine top-line results for Phase 2/3 SAGA clinical trial expected in Q1 2017
January 4, 2017 / 1:26 PM / in 10 months

BRIEF-Aevi Genomic Medicine top-line results for Phase 2/3 SAGA clinical trial expected in Q1 2017

Jan 4 (Reuters) - Aevi Genomic Medicine Inc :

* Aevi Genomic Medicine announces completion of enrollment for Phase 2/3 SAGA clinical trial of AEVI-001 (NFC-1) in MGLUR+ ADHD adolescents

* Aevi Genomic Medicine Inc- top-line results expected in Q1 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below